In the case of MS, RGMa has been reported as upregulated in disease lesions (13), and in the experimental autoimmune encephalomyelitis (EAE) mouse model, anti-RGMa neutralizing antibody treatment was shown to attenuates motor symptoms by modulating T cell responses (12). The gene discussed is RGMA; the disease is myeloid sarcoma.